Contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products)
In the opinion of the site investigator or primary clinical care team, anticipated to die within 48 h
Acute or chronic disease/illness that, in the opinion of the site investigator, has an expected life expectancy of < 28 days unrelated to COVID‐19‐induced pneumonia (e.g. stage IV malignancy, neurodegenerative disease, anoxic brain injury, etc.)
Use of home oxygen at baseline
Use of home mechanical ventilation at baseline (CPAP or bi‐level positive airway pressure without need for oxygen is NOT an exclusion)
Respiratory failure caused by illness other than SARS‐CoV‐2
Other documented uncontrolled infection
> 72 h have elapsed since first meeting inclusion criteria
Severe disseminated intravascular coagulation, TTP, or antithrombin III deficiency needing factor replacement, fresh‐frozen plasma, cryoprecipitate
On warfarin and deemed necessary to maintain therapeutic international normalised ratio (because the CP will reverse the warfarin effect)
On dialysis at the time enrolment is considered
Active intracranial bleeding
Clinically significant myocardial ischaemia
Prisoner or incarceration
Pregnancy or active breast feeding
Has already received CP for COVID‐19 infection during current admission
Current participation in another interventional research study
Inability or unwillingness of subject or legal surrogate/representative to give written informed consent